Rising Losses and New CEO: What’s Next for Archer Materials’ Quantum Ambitions?
Archer Materials has made notable advances in its quantum computing and biosensor technologies during FY25, alongside leadership changes and a widened net loss. The company’s progress signals growing momentum in its commercialisation efforts.
- Demonstrated Coulomb blockade at room temperature in quantum project
- Spin coherence times for qubit material more than doubled
- Integrated proprietary biosensor with CMOS circuitry for medical diagnostics
- Appointed Dr Simon Ruffell as new CEO and formed Advisory Committee
- Reported $6.97 million net loss, up 45% from prior year, with $13.7 million cash reserves
Quantum Breakthroughs
Archer Materials has reported significant technical milestones in its 12CQ quantum project, including the demonstration of the Coulomb blockade phenomenon at room temperature, a critical step toward practical quantum computing devices. The company also designed a new resonator circuit that achieved strong coupling between spin states of its proprietary carbon-based material and superconducting resonators, edging closer to a functional qubit.
Notably, Archer doubled the spin coherence times of its qubit film material from approximately 385 nanoseconds to around 800 nanoseconds under certain conditions, enhancing the stability and reliability of its quantum bits. The fabrication of superconducting circuits with multiple resonators further supports improved quantum readout capabilities.
Advances in Biosensor Technology
Parallel to its quantum efforts, Archer’s Biochip platform has integrated proprietary biosensor technology with CMOS readout circuitry, a key step toward scalable medical diagnostic devices. The company has partnered with leading research institutions to refine blood testing performance and develop an integrated potassium testing cartridge, targeting chronic kidney disease applications.
Efforts to miniaturise the biosensor chip design aim to reduce costs and improve scalability, while a new conditioning protocol has enhanced test repeatability by up to tenfold, underscoring Archer’s commitment to practical, reliable diagnostics.
Leadership and Corporate Strategy
In March 2025, Archer appointed Dr Simon Ruffell as CEO, signaling a strategic push to accelerate commercialisation. The establishment of a highly credentialed Advisory Committee further supports this objective, providing expert guidance on technology development and market entry.
Financially, Archer reported a net loss of $6.97 million for FY25, a 45% increase from the previous year, primarily driven by research and development expenses and share-based payments. Despite this, the company maintains a robust cash position of $13.7 million with no debt, underpinning ongoing innovation and development activities.
Executive Chairman Greg English highlighted the company’s progress as a testament to Archer’s innovation and global collaboration, emphasizing the dual-track advancement of quantum computing and biosensor platforms as central to its future growth.
Bottom Line?
Archer’s technical strides and leadership changes set the stage for a pivotal year ahead as it seeks to translate innovation into commercial success.
Questions in the middle?
- When can Archer realistically expect commercial revenue from its quantum and biosensor technologies?
- How will new CEO Dr Simon Ruffell’s strategy impact partnerships and funding?
- What are the key market opportunities Archer aims to prioritise for its TMR sensor technology?
